As of Jul 02
| -0.15 / -5.66%|
The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 8.00, with a high estimate of 10.50 and a low estimate of 5.00. The median estimate represents a +220.00% increase from the last price of 2.50.
The current consensus among 3 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.